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ABSTRACT 
Zika virus (ZIKV) is a mosquito-borne flavivirus distributed all over Africa, South America and Asia. The infec-
tion with the virus may cause acute febrile sickness that clinically resembles dengue fever, yet there is no vaccine, 
no satisfactory treatment, and no means of evaluating the risk of the disease or prognosis in the infected people. 
In the present study, the efficacy of the host’s immune response in reducing the risk of infectious diseases was 
taken into account to carry out immuno-informatics driven epitope screening strategy of vaccine candidates against 
ZIKV. In this study, HLA distribution analysis was done to ensure the coverage of the vast majority of the popu-
lation. Systematic screening of effective dominant immunogens was done with the help of Immune Epitope & 
ABCPred databases. The outcomes suggested that the predicted epitopes may be protective immunogens with 
highly conserved sequences and bear potential to induce both protective neutralizing antibodies, T & B cell re-
sponses. A total of 25 CD4+ and 16 CD8+ peptides were screened for T-cell mediated immunity. The predicted 
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epitope "TGLDFSDLYYLTMNNKHWLV" was selected as a highly immunogenic epitope for humoral immun-
ity. These peptides were further screened as non-toxic, immunogenic and non-mutated residues of envelop viral 
protein. The predicted epitope could work as suitable candidate(s) for peptide based vaccine development. Further, 
experimental validation of these epitopes is warranted to ensure the potential of B- and T-cells stimulation for their 
efficient use as vaccine candidates, and as diagnostic agents against ZIKV. 
 
Keywords: Zika virus, HLA, vaccine, prophylactic, immunogens, B-/T-cell 
 
Abbreviations: ZIKV: Zika virus; NCR: non-coding regions; ORF: open reading frame; MHC: major histocom-
patibility complex; HLA: human leukocyte antigen 
 
 
 
INTRODUCTION 
Zika virus (ZIKV), a pathogenic vector 
borne flavivirus is a member of the Flaviviri-
dae family, transmitted by the Aedes mosqui-
toes and is known to cause Zika fever. This 
virus was first identified in the blood of a sen-
tinel Rhesus monkey during a study on Yel-
low fever in the Zika forest of Uganda in 
1947. This was followed by subsequent isola-
tion of this virus from a pool of Aedes mos-
quitoes of African region (Dick et al., 1952). 
Since then, several outbreaks of Zika have 
been reported in humans in Africa and Asia. 
Currently, it has been reported in Brazil, the 
Pacific region, and is also known to spread 
widely in Central and South America.  
The Zika fever illness is generally charac-
terized by some of the symptoms which are 
similar to other arbovirus infections like Den-
gue and Chikungunya. These symptoms in-
clude fever, malaise, conjunctivitis, rashes on 
skin, anorexia, headache as well as pain in the 
muscles and joints (Simpson, 1964). In case 
of pregnant women, Zika virus may spread 
from the mother to the fetus and is believed to 
be associated with microcephaly, a serious 
birth defect characterized by smaller and 
poorly developed brain in the newborns (Tor-
jesen, 2016). Pregnant women are therefore 
advised to avoid traveling to areas prone to in-
cidence of Zika. Zika virus has 25-30 nm nu-
cleocapsid, which is surrounded by a lipid bi-
layer containing envelope proteins. It has a 
single stranded RNA genome with 10,141 
base pairs accountable for encoding of nearly 
3380 amino acids (Fonseca et al., 2014). The 
virus has two flanking 5’ and 3’ non-coding 
regions (NCR) and a long open reading frame 
(ORF) “59-C-prM-E-NS1-NS2A-NS2BNS3-
NS4A-NS4B-NS5-39” coding for a polypro-
tein that cleaves into its envelope (E), capsid 
(C), precursor membrane (prM), and some 
other non-structural (NS) proteins (Chambers 
et al., 1990; Kuno et al., 2007). Zika virus is 
maintained through a sylvatic transmission 
cycle. The envelope protein is the major sur-
face protein of the virus, and is involved in 
various aspects of the viral cycle and is be-
lieved to mediate binding and membrane fu-
sion (Lindenbach et al., 2003). The non-struc-
tural protein, NS5 has RNA-dependent RNA 
polymerase (RdRP) that acts at its C-terminal, 
while the N-terminal is involved in RNA cap-
ping (Lindenbach and Rice, 2003). The 3’ 
non-coding region is made up of about 428 
nucleotides having 27 folding patterns (Kuno 
et al., 2007), which are believed to be in-
volved in the processes like translation, stabi-
lization of the genome, packaging of RNA, 
and recognition of the cellular or the viral fac-
tors (Lindenbach and Rice, 2003).  
Due to lack of rapid diagnostic tech-
niques, effective treatment and availability of 
novel vaccines against the Zika virus has been 
a public health emergency of the international 
concern declared by the World Health Organ-
ization (Salaam-Blyther, 2016). Hence, it is 
necessary to develop a substantial amount of 
immunity in humans against Zika virus to pre-
vent the widespread outbreak of the infection 
and its associated effects. Taking a step to-
wards this development, we screened the im-
munogenic epitopes of the envelope protein 
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of Zika virus using an in silico approach. This 
might be helpful in developing peptide based 
vaccines against the Zika virus. 
 
MATERIALS AND METHODS 
Sequence retrieval 
The 504 length amino acid sequence of vi-
ral envelope (E) protein (GenBank: 
AIC06934.1 & RCSB PDB ID: 5IZ7), in-
volved in the host cell binding and fusion ac-
tivity was retrieved from UniprotKB Data-
base (www.uniprot.org). The retrieved se-
quence (A0A060H177_9FLAV E protein) 
was a further subjected to immunogenicity as-
sessment and epitope prediction.  
 
Immunogenicity prediction of the viral pro-
tein 
The VaxiJen V2.0 server 
(http://www.ddg-pharmfac.net/vaxijen/Vaxi-
Jen/VaxiJen.html) was used for the evaluation 
of immunogenicity of the retrieved protein se-
quence. This server works on Auto Cross Co-
variance (ACC) algorithm that predicts pro-
tective antigens, tumor antigens, and subunit 
vaccines with the precision level of 70 to 
89 % for the discrimination between antigens 
and non-antigens (Doytchinova and Flower, 
2007). 
 
Epitope prediction 
(a) B-cell epitope prediction 
B-cell epitopes were predicted using an 
ABCPred online server 
(www.imtech.res.in/abcpred) by selecting the 
window length of 20 amino acids, which were 
recommended for humaoral immunity. This 
server is based on information - processing al-
gorithms inspired by the biological nervous 
system. The server ranks the epitopes as per 
their respective scores. The higher score of 
the peptides means a greater probability of be-
coming most suitable immunogenic epitope 
(Saha et al., 2006). 
 
(b) CD4+ and CD8+ epitope prediction 
 The envelop protein sequence was ana-
lyzed for the screening of the possible domi-
nant T-cell epitopes using immuno-informat-
ics (Immune Epitope Database) tool IEDB 
online server (www.iedb.org) (Bui et al., 
2006). Human leukocyte antigen (HLA)-I and 
HLA-II binding resources present in the 
IEDB, were used for the binding analysis of 
all the possible peptides considering the pres-
ence of all the HLAs in the database. The pep-
tide length was set to be 10 and 15 for HLA-I 
and HLA-II, respectively. Default IEDB rec-
ommended prediction method combines the 
predictions from ANN, SMM, and CombLib 
algorithms. The epitopes were predicted on 
the basis of lowest percentile rank and high 
binding affinity. 
 
Antigenicity of the identified epitopes 
The immunogenicity of both B-cell and T-
cell predicted epitopes was evaluated using a 
VexiJen V2.0 online server (http://www.ddg-
pharmfac.net/vaxijen/VaxiJen/VaxiJen.html) 
 
Determination of conserved regions &  
toxicity of the identified epitopes 
The immunogenic epitopes were checked 
for the conserved regions and further sub-
jected to ToxinPred severe (Gupta et al., 
2013) for the differentiation of toxic or non-
toxic peptides. The ToxinPred server is based 
on Support Vector Machine (SVM) and 
Quantitative Matrix based algorithm, and 
generates quantitative matrix on the basis of 
probability or frequency of amino acid at a 
particular position.  
 
Determination of physico-chemical proper-
ties of the identified epitopes 
The Peptide Property Calculator 
(https://www.genscript.com) server was used 
to determine the best solvent for the predicted 
peptide based on its amino acid sequence. 
 
Population coverage analysis 
Due to the dependence of major histocom-
patibility complex (MHC) of T-cell response, 
the peptides with wide range of HLA binding 
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specificities result in wider population cover-
age in terms of geographical expansion. The 
population coverage rate of the predicted 
epitopes was calculated by employing the 
IEDB population coverage tool 
(http://tools.immuneepitope.org/tools/popu-
lation/iedb_input)(Bui et al., 2006). The pre-
dicted epitopes with its all binding HLA al-
leles for the worldwide distribution were tab-
ulated. The schematic representation of the 
entire methodology of in silico CD4+, CD8+ 
T-cell & B-cell epitope prediction and HLA 
distribution of Zika virus is given in Figure 1. 
 
 
Figure 1: Schematic representation of the entire 
in silico strategy of CD4+, CD8+ T-cell and B-cell 
epitope prediction and HLA distribution of Zika vi-
rus 
 
RESULTS 
Protein immunogenicity and epitope identi-
fication 
The immunogenicity of the viral envelope 
protein was ensured using VaxiJen V2.0 
online server, keeping the threshold at 0.4. 
The results obtained suggest that the viral se-
quence is a probable antigen with a score of 
0.6178. The prediction and identification of 
B-cell epitopes in target antigens, being a key 
step in the epitope based vaccine develop-
ment, was performed by using ABCPred 
server. Based on the artificial neural network 
(ANN) method, the epitopes predicted by 
ABCPred were in the descending order of 
their scores, depicting that the top most has 
the best binding affinity. Therefore, the first 
(top) epitope ‘TGLDFSDLYYLTMNN-
KHWLV’ with the score 0.90 at the position 
194 to 213 showing the highest probability to 
be an antigenic determinant, was selected for 
further study.  
MHC-II restricted CD4+ T-cells activa-
tion plays an important role in initiating and 
upholding a proficient antibody response or 
cytotoxic T-lymphocytes (CTL) response. 
Further, MHC-I restricted CD8+ CTLs have a 
vital role in combating the viral infection. 
Thus, the comprehending principles of T-cell 
activation and epitope-based vaccine design, 
direct the identification of helper T-cell 
epitopes and CTL epitopes. The helper T-cell 
epitopes and CTL epitopes in the ‘Env’ pro-
tein of Zika virus were identified using the 
IEDB online tool. The immunogenic peptides 
were ranked in accordance with their consen-
sus percentile rank from SWISS-PROT pro-
gram. The lowest percentile rank demon-
strated as the best binders. By selecting the 
first (lowest percentile rank) epitope for each 
of HLA class-II and HLA class-I gave 63 
helper T-cell epitopes (Supplementary Infor-
mation: Table S1) and 76 CTL epitopes (Sup-
plementary Information: Table S2). 
 
Conserved regions and immunogenicity of 
the identified epitopes 
Peptides with strong antigenicity are al-
ways better candidates to be B- and T-cell 
epitopes than those with weak antigenicity. 
Hence, the assessment of immunogenicity of 
the identified peptides was performed using 
the VaxiJen V2.0 server (http://www.ddg-
pharmfac.net/vaxijen/VaxiJen/VaxiJen.html). 
This tool predicts the antigenicity of a peptide 
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on the basis of amino acid properties and their 
positions in the peptide. The results demon-
strated that the identified B-cell epitope is im-
munogenic in nature with score of 1.2758, 
and among all the identified T-cell epitopes, a 
total of 16 HLA class-II and 25 HLA class-I 
epitopes were found to be conserved as well 
as immunogenic (Supplementary Infor-
mation: Table S3).  
 
Toxicity and solvency analysis 
The final epitope set (B- and T-cell 
epitopes) was further tested for the toxicity 
analysis and medium solvency. All the pre-
dicted immunogenic epitopes were non-toxic 
and were classified as acidic, basic or neutral 
(Table 1). Acidic peptides were initially dis-
solved in water, if not, then < 50 µl NH4OH 
was added and diluted to 1 ml with deionized 
water. For basic peptides, 10 % and higher so-
lutions of acetic acid was tried; in case not dis-
solved, then < 50 µl TFA was added and di-
luted up to 1 ml with deionized water to solu-
bilize the peptide. Neutral peptides required 
organic solvents like acetonitrile, methanol, 
or isopropanol. 
 
Population coverage analysis 
HLA allocation varies among diverse eth-
nic groups spread over different geographical 
regions of the world. Therefore, while design-
ing a potent vaccine, population coverage 
must be taken into account to cover maximum 
possible populations. In this study, all alleles 
in IEDB database were identified as best 
binders with the predicted epitopes and were 
used to establish the population coverage for 
these epitopes (Table 2). A significant per-
centage of the specific area population cover-
age of all the identified immunogenic 
epitopes was found all over the world.  
 
DISCUSSION  
Vaccination appears to be the most opti-
mal and successful strategy to reduce the 
menace of dreadful infectious diseases world-
wide. Currently, the immune-informatics ap-
proach is the most promising approach for the 
development of peptide based vaccines. Due 
to lack of effective treatment for the micro-
cephaly caused by Zika virus, there is an ur-
gent need for a cost effective vaccine against 
this deadly virus. Earlier studies have already 
demonstrated that application of potential 
epitope(s) instead of whole protein as a vac-
cine has been confirmed to represent the com-
plete antigenicity of any protein (DeGroot et 
al., 2002). Also, in the recent past, the epitope 
based vaccines have given promising results 
against highly infectious diseases such as 
H1N1, HIV and Tuberculosis (Correia et al., 
2014). These vaccines may have a lower 
chance of eliciting immune response against 
self-antigens, thereby avoiding autoimmune 
responses (Aziz et al., 2008). The traditional 
molecular immunology techniques used to 
search for immunogenic peptides to be used 
as vaccine candidates are extensively time 
consuming, labour intensive, and expensive. 
However, as a remedy, in recent years, vari-
ous computational approaches have been pro-
posed and tested by many researchers to re-
duce the time, cost, and labour involved (Da-
vies and Flower, 2007; Shi et al., 2015). On 
the similar lines, the suggested in silico strat-
egy might prove as a boon for the experi-
mental biologists in rapid screening and iden-
tification of probable vaccine candidates. T-
lymphocytes play a central role in the genera-
tion of a protective immune response in many 
microbial infections (Esser et al., 2003), 
hence the prediction and screening of T-cell 
epitopes can be exploited as a potential vac-
cine candidate is a critical requirement for the 
designing of epitope-based vaccines.  
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Table 1: Prediction of most immunogenic, non-mutant and non-toxic B-cell and T-cell epitopes of the 
envelope protein of Zika virus (the threshold immunogenicity of the peptides was 0.4 and the total pre-
dicted range of VaxiJen score was from 2.0901 to 0.4505) 
No. Peptides/Epitopes Start End Percentile 
Rank 
Immunogenicity Tox-
icity 
Attrib-
ute 
                 B-cell epitopes Thresh-
old 
VaxiJen 
Score* 
1 TGLDFSDLYYLTMNNKHWLV 194 213 0.90 0.4 1.2758  Non-
Toxic 
neutral 
                T-cell epitopes 
  HLA Class-I 
1 SLMCLALGGV HLA-A*02:01, 
HLA-A*02:06 
485 494 0.2 0.4 1.7363   Non-
Toxic 
Neutral 
2 LLMWLGLNTK HLA-A*03:01 471 480 0.25 0.4 1.8391  Non-
Toxic 
Basic 
3 EATLGGFGSL HLA-A*25:01 177 186 1.7 0.4 1.0328  Non-
Toxic 
Acidic 
4 ELDPPFGDSY HLA-A*26:01 377 386 0.9 0.4 0.6953   Non-
Toxic 
Acidic 
5 NMAEVRSYCY HLA-A*29:02, 
HLA-B*15:01 
52 61 0.3 0.4 1.2831 Non-
Toxic 
Neutral 
6 KAFEATVRGA HLA-A*30:01 409 418 1.35 0.4 0.9016  Non-
Toxic 
Basic 
7 RTGLDFSDLY HLA-A*30:02 193 202 0.25 0.4 1.8346  Non-
Toxic 
Acidic 
8 RLSSGHLKCR HLA-A*31:01, 
HLA-A*74:01 
283 292 0.7 0.4 2.0901  Non-
Toxic 
Basic 
9 DMQTLTPVGR HLA-A*33:03, 
HLA-C*04:01 
348 357 0.7 0.4 0.8543  Non-
Toxic 
Neutral 
10 TTVSNMAEVR HLA-A*02:01, 
HLA-A*02:06 
48 57 0.2 0.4 0.7175  Non-
Toxic 
Neutral 
11 TTTVSNMAEV HLA-A*03:01 47 56 0.3 0.4 0.6972   Non-
Toxic 
Acidic 
12 TPHWNNKEAL HLA-A*25:01 233 242 0.35 0.4 1.5710  Non-
Toxic 
Basic 
13 LRLKGVSYSL HLA-A*26:01 298 307 0.35 0.4 1.1682  Non-
Toxic 
Basic 
14 VDIELVTTTV HLA-A*29:02, 
HLA-B*15:01 
41 50 0.6 0.4 1.3702   Non-
Toxic 
Acidic 
15 KMMLELDPPF HLA-A*30:01 373 382 0.2 0.4 1.0318   Non-
Toxic 
Acidic 
16 AETLHGTVTV HLA-A*02:01, 
HLA-A*02:06 
319 328 0.3 0.4 0.5422  Non-
Toxic 
Neutral 
17 HHWHRSGSTI HLA-A*03:01 398 407 0.3 0.4 0.4776  Non-
Toxic 
Basic 
18 RMAVLGDTAW HLA-A*25:01 420 429 0.2 0.4 0.8599  Non-
Toxic 
Neutral 
19 YCYEASISDM HLA-A*26:01 59 68 0.2 0.4 1.0191  Non-
Toxic 
Acidic 
20 AHAKRQTVVV HLA-A*29:02, 
HLA-B*15:01 
248 257 0.3 0.4 0.7216  Non-
Toxic 
Basic 
21 SRCPTQGEAY HLA-A*30:01 72 81 0.9 0.4 0.6146  Non-
Toxic 
Neutral 
22 FGDSYIVIGV HLA-A*30:02 382 391 0.2 0.4 0.6413  Non-
Toxic 
Acidic 
23 DAHAKRQTVV HLA-A*31:01, 
HLA-A*74:01 
247 256 0.5 0.4 0.6538  Non-
Toxic 
Basic 
24 ESTENSKMML HLA-A*33:03, 
HLA-C*04:01 
367 376 0.5 0.4  0.4843  Non-
Toxic 
Acidic 
25 AVDMQTLTPV HLA-A*68:01 346 355 0.4 0.4 0.7836  Non-
Toxic 
Acidic 
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No. Peptides/Epitopes Start End Percen-
tile 
Rank 
Immunogenicity Tox-
icity 
Attrib-
ute 
                 B-cell epitopes Thresh-
old 
Vaxi-
Jen 
Score* 
1 TGLDFSDLYYLTMNNKHWLV 194 213 0.90 0.4 1.2758
  
Non-
Toxic 
neutral 
                T-cell epitopes 
 HLA Class-II 
1 RTGLD-
FSDLYYLTMN 
HLA-DPA1*01/DPB1*04:01 193 207 0.61 0.4 1.4016
  
Non-
Toxic 
Acidic 
2 PRTGLD-
FSDLYYLTM 
HLA-
DPA1*01:03/DPB1*02:01 
192 206 0.05 0.4 1.4164
   
Non-
Toxic 
Acidic 
3 WLVHKEW-
FHDIPLPW 
HLA-
DQA1*01:01/DQB1*05:01 
211 225 0.52 0.4 0.6855
  
Non-
Toxic 
Basic 
4 NTKNGSISLM-
CLALG 
HLA-
DQA1*01:02/DQB1*06:02 
478 492 1.15 0.4 1.9904
  
Non-
Toxic 
Basic 
5 AVHTALA-
GALEAEMD 
HLA-
DQA1*03:01/DQB1*03:02,  
HLA-
DQA1*04:01/DQB1*04:02, 
HLA-
DQA1*05:01/DQB1*02:01 
264 278 0.79 0.4 0.4323
  
Non-
Toxic 
Acidic 
6 EGAVHTALA-
GALEAE 
HLA-
DQA1*05:01/DQB1*03:01 
262 276 0.93 0.4 0.4632
  
Non-
Toxic 
Acidic 
7 QPENLEYRIM-
LSVHG 
HLA-DRB1*01:02, HLA-
DRB1*04:08, 
HLA-DRB1*04:10, HLA-
DRB1*04:21, 
HLA-DRB1*04:26, HLA-
DRB1*11:20, 
HLA-DRB1*11:28, HLA-
DRB1*13:05, 
HLA-DRB5*01:05 
131 145 0.23 0.4 0.4589
  
Non-
Toxic 
Neutral 
8 EPRTGLD-
FSDLYYLT 
HLA-DRB1*03:01 191 205 0.72 0.4 1.1568
  
Non-
Toxic 
Acidic 
9 RLKMDKLRL-
KGVSYS 
HLA-DRB1*03:05, HLA-
DRB1*04:02, 
HLA-DRB1*08:04, HLA-
DRB1*08:06, 
HLA-DRB1*08:13, HLA-
DRB1*11:02, 
HLA-DRB1*11:07, HLA-
DRB1*11:14, 
HLA-DRB1*11:21, HLA-
DRB1*13:01, 
HLA-DRB1*13:04, HLA-
DRB1*13:22, 
HLA-DRB1*13:23, HLA-
DRB1*13:27  
292 306 0.67 0.4 0.7441
  
Non-
Toxic 
Basic 
10 GTLLMWLGLN
TKNGS 
HLA-DRB1*03:06, HLA-
DRB1*03:07,  
HLA-DRB1*03:08,  
469 483 0.18 0.4 1.2662
  
Non-
Toxic 
Basic 
11 DFSDLYYLT-
MNNKHW 
HLA-DRB1*04:01 197 211 0.11 0.4 1.1408
   
Non-
Toxic 
Neutral 
12 LALGGVLIFLS
TAVS 
HLA-DRB1*04:04, HLA-
DRB1*04:23, 
HLA-DRB1*08:02, HLA-
DRB1*11:01,  
HLA-DRB1*11:04, HLA-
DRB1*11:06, 
HLA-DRB1*13:07, HLA-
DRB1*13:11  
489 503 0.3 0.4 0.4505
  
Non-
Toxic 
Neutral 
13 FSDLYYLT-
MNNKHWL 
HLA-DRB1*04:05 198 212 0.3 0.4 0.8870
  
Non-
Toxic 
Basic 
14 PRAEAT-
LGGFGSLGL 
HLA-DRB1*07:03, HLA-
DRB1*15:02, 
HLA-DRB1*15:06 
174 188 0.58 0.4 1.4679
  
Non-
Toxic 
Neutral 
15 CLALGGVLIFL
STAV 
HLA-DRB1*15:01 488 502 0.07 0.4 0.5558
  
Non-
Toxic 
Neutral 
16 ENSKMM-
LELDPPFGD 
HLA-DRB3*01:01 370 384 0.01 0.4 0.7744
  
Non-
Toxic 
Acidic 
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Table 2: Prediction of population coverage rate (%) of MHC Class-I and MHC Class-II 
S.N
o. 
MHC Class-1 MHC Class-II 
Population / 
Area 
Coverage a Average 
hit b 
PC90 c Cover-
age a 
Average 
hit b 
PC90 c 
1 East Asia 91.33% 1.88 1.05 98.78% 3.29 2.05 
2 Northeast Asia 82.73% 1.46 0.58 99.78% 4.13 2.74 
3 South Asia 91.88% 1.94 1.07 99.93% 4.72 3.26 
4 Southeast Asia 82.82% 1.44 0.58 98.75% 3.18 2.01 
5 Southwest Asia 90.46% 1.83 1.02 99.62% 4.02 2.57 
6 Europe 98.67% 2.85 1.88 99.99% 5.36 3.98 
7 East Africa 95.00% 2.18 1.23 100.00% 5.25 4.01 
8 West Africa 93.74% 2.08 1.15 99.97% 5.00 3.63 
9 Central Africa 94.33% 2.14 1.19 99.94% 4.57 3.20 
10 North Africa 95.49% 2.24 1.26 99.85% 4.44 3.06 
11 South Africa 96.61% 2.32 1.35 45.98% 0.49 0.19 
12 West Indies 88.48% 1.57 0.87 99.41% 3.46 2.24 
13 North America 96.52% 2.35 1.35 100.00% 5.92 4.54 
14 Central America 6.25% 0.06 0.11 99.99% 4.26 3.16 
15 South America 88.06% 1.65 0.84 100.00% 5.13 3.83 
16 Oceania 74.87% 1.17 0.40 99.95% 4.88 3.41 
Average 
(Standard deviation) 
83.71 
(22.26%) 
1.71 
(0.57) 
0.91 
(0.35) 
96.37% 
(13.02%) 
4.26 
(1.22) 
2.99 
(1.01) 
 
 
Recently, a similar approach was used for 
the identification of highly immunogenic pep-
tides of Env protein of Zika virus (Badawi et 
al., 2016) and suggested highly recommended 
T cell epitopes MMLELDPPF as therapeutic 
peptide vaccine to interact with MHC class I 
along with three other epitopes 
MAVLGDTAW, KEWFHDIPL and DTAW-
DFGSV. Also, three epitopes showed high af-
finity to interact with MHC class II alleles i.e., 
FKSLFGGMS, LITANPVIT and VHTALA-
GAL. Alam et al. (2016) proposed MHC 
class-I potential peptides YRIMLSVHG, 
VLIFLSTAV and MMLELDPPF, GLD-
FSDLYY as potent peptide epitopes for  
CD4+ and CD8+ T-cells,  respectively. The 
current study was aimed to identify B-cell, T-
cell highly immunogenic, non toxic and non 
variable peptides which have maximum 
world population coverage area. 
The sequence of the viral envelope protein 
was used for the evaluation of the viral immu-
nogenicity to predict the vaccine candidates 
against the immune-responses of B- and T-
cells. The B-cell epitope and the best/highest 
percentile score generated a single epitope 
‘TGLDFSDLYYLTMNNKHWLV’ at a po-
sition of 194 to 213 with immunogenic score 
1.2758. The putative CD4+ & CD8+ T-cell 
core epitopic sequences for all the HLA super 
types were predicted. We also checked our 
predicted immunogenic epitopes for the con-
served regions and further subjected them to 
ToxinPred server for the differentiation of 
toxic or non-toxic peptides. The assessment 
of the immunogenicity and toxicity properties 
of the putative epitopes using various online 
servers showed that the predicted epitopes 
were immunogenic in nature, and no se-
quence variability was detected in the region 
containing the potential epitopes. 
The epitope NTKNGSISLMCLALG at 
position 478-492 for HLA Class-II and the 
epitope RLSSGHLKCR at position 283-292 
for HLA Class-I was found to have the high-
est antigenic score of 1.9904 and 2.0901, re-
spectively, and both were found to be basic in 
nature (Table 1).  
The putative epitopes have excellent 
worldwide population coverage as depicted in 
Table 2, and may provide worldwide immune 
protection (83.71 % of the average MHC 
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Class-I coverage and 96.37 % of the average 
MHC Class-II coverage) against ZIKV.  
The application of in silico approaches by 
immunologists has helped to speed up the in 
vitro, in vivo and ex vivo studies by cutting 
down the large epitope dataset into a smaller 
one that needs to be confirmed by the experi-
mental analysis. The predictions made by the 
present study on the primary amino acid se-
quence of Zika virus should help other re-
searchers to experimentally verify the im-
muno-dominant epitopes fundamental to the 
understanding of the pathobiology of Zika vi-
rus leading to effective vaccine development. 
The data from the current work on B- and 
T-cell peptide epitopes for ‘Env’ protein of 
Zika virus might prove a milestone in the de-
velopment of vaccines to combat Zika virus 
induced infection. The suggested in silico 
strategy might prove as a boon for the experi-
mental biologists in rapid screening and iden-
tification of probable vaccine candidates. The 
proposed non–toxic epitopes would be a rele-
vant representative of a large proportion of 
the human population. This work indicates 
that the proposed epitopes prompt the future 
vaccine development against the Zika virus. 
However, the potential of the screened 
epitopes by experimental validation is war-
ranted. 
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